Z-LEHD-fmk Options
The main close stage was the protection and tolerability of sifalimumab. Procedure-emergent adverse occasions (AEs) and severe AEs (SAEs) and their severity, result, and any relationship for the research medication have been recorded via the investigator through the entire analyze. AEs were deemed more likely to be associated with research medicati